AM1241, a Canabinoid ligand against cancer pain

In animal models CB(2) selective agonists have been shown to reduce bone loss. This gave rise to the ideas of checking the efficacy of this Cannabinoid in bone cancer-induced pain .

A murine bone cancer model was used  and AM1241 was administered acutely or for 7days. It significantly attenuated spontaneous and evoked pain. Furthermore, sustained AM1241 significantly reduced bone loss and decreased the incidence of cancer-induced bone fractures.

The authors concluded:

These findings suggest a novel therapy for cancer-induced bone pain, bone loss and bone fracture while lacking many unwanted side effects seen with current treatments for bone cancer pain.  ^[1]

From the Centre for the study and treatment of neuropathic pain and neuropathy in Soest, the Nertherlands

This site helps patients and treating physicians, neurologists, anesthesiologists and other pain specialists to find the best and most up to date research findings related to neuropathy and neuropathic pain and the treatment thereof.

In our centre we are specialised in treating patients suffering from neuropathic pain and neuropathy following an Integrated Medicine concept. Part of our activities are within the field of consultation. We assist pharmaceutical companies in R&D strategies related to finding new drugs to treat neuropathic pain and neuropathy.

February 2010, Jan M. Keppel Hesselink, MD, PhD.

Referenties